The Take — Overvalued. The market is capitalizing a record margin, a tariff refund and a 5.2% risk-free rate as if none of them were temporary.
The PEG is low because the "E" just jumped on things that don't repeat. TTM EPS is up 52% to $2.47. Of Q2-26's 524bp gross-margin jump, ~393bp was a $15.6M IEEPA tariff refund booked against cost of sales — management's own H2 guide (≈40.8% adj. GM in Q3) gives most of it back, and it flags higher raw-material and energy costs for H2. Strip the refund and TTM clean EBIT margin is 12.1%; FY26E ex-refund is 12.3%.
That's the best margin in at least ten years. Over 2016–2025 — a full cycle that includes the nora acquisition, the 2020 COVID office collapse, two goodwill write-downs ($121M in 2020, $36M in 2022) and near-continuous restructuring — clean EBIT margin averaged 9.5% and never exceeded 11.8%. Management deserves credit: One Interface consolidation, price/mix and automation have lifted the structural base, and we give that credit in full — base case holds 11.5% forever, two points above the 10-yr average. That's worth $23.74. Even holding today's 12.3% in perpetuity gets only $25.50; the bull case (13%, 4–5% growth) $28.47. Nothing in our range reaches $34.87.
Reverse DCF: the price needs a ~16.3% steady margin (never achieved; ~4pt above today), or growth ~3.3x our path (~10%/yr for a decade in a flooring market growing low-single digits), or a WACC of ~7.9% — an equity cost below 9% with the 10-year at 5.2%. TILE trades at 12.6x ex-refund EBIT and a 5.3% FCF-after-SBC yield: a bond-like yield on a cyclical, nylon-input, office-exposed manufacturer.
The bull counter, honestly stated: 2025 revenue ($1.39B) is barely above 2019's ($1.34B) in nominal terms — ~17% lower in real volume. Record margins at sub-peak volume suggest real structural improvement, and an office re-leasing cycle could add operating leverage. Backlog is up ~22% YTD and orders +5%. That's why we're at 11.5% not 9.5%, and why the bull case exists. It still doesn't get you to the price.
Call:AVOID new money; holders TRIM above ~$30. Accumulate only below ~$21 (≈10% under base; ≈ value at the 10-yr-average margin), which is where a normal flooring down-cycle would take it. For holders who won't sell: write $40 covered calls (above the Aug-9 post-earnings spike of $38.29). Bear expression, defined risk only: a Dec/Jan $40/$45 bear call spread after the early-November Q3 print — the catalyst list (refund roll-off, H2 raw-material headwind, 53rd-week comp in Q1-27) skews negative, but balance sheet strength (0.5x levered, buybacks) makes naked shorts a bad idea. Options are thin; work limits.
Risk Profile — MEDIUM
HIGH
Corporate-office cycle / hybrid work — ~44% of sales into office renovation, which lags vacancy and capex budgets by 6–12 months. 2020 showed the downside: sales −18%, clean margin 8.0%. Long: office re-leasing; short: vacancy, tighter credit for landlords (Rf 5.2%).
HIGH
Raw materials (nylon 6/6,6 yarn, PVC/backings, synthetic rubber, energy) — petrochemical-linked inputs ≈ half of $857M COGS (est.). A 10% move with 50% price recovery = ±1.5pt margin ≈ ±$3.45/share. Short: crude/caprolactam, European energy.
MED
Tariffs / trade — the $15.6M IEEPA refund is a one-off reversal of prior tariff cost; new Section 232/301 actions on imported tile, LVT (Asia-sourced) or rubber could reverse it. Two-way.
MED
FX — EAAA (~37% of sales: Europe, UK, Australia, Asia) — Q2 sales +3.8% currency-neutral vs +5.4% reported. Long: EUR/AUD.
LOW
Balance sheet — net debt $123M (0.5x), $216M undrawn revolver, notes due 2030. Lease ($86M) and European pension (~$40M est.) liabilities included as debt.
LOW
Mix upside — healthcare billings +19%, education +5%: the non-office ~36% is less cyclical and carries nora rubber's higher margins. Long.
What the "inventory" really is: a nylon-to-carpet-tile converter with a premium brand and design-specification moat in commercial interiors. Its earnings power is the spread between specified-product pricing and petrochemical input cost, multiplied by office renovation volume — both cyclical. The current print sits at the favorable corner of both.
Scenario values per share vs price
Bear: office downturn (−6%/−3% sales in 2027–28), margin reverts to 10-yr avg 9.5%. Base: 2–4% growth, margin fades 12.3%→11.5%. Bull: 4–5% growth, 13.0% margin. Prob-weighted 25/50/25 = $23.37. Bear is shallow ($17.54) because leverage is low — the downside is valuation, not solvency.
Driver tornado — value/share from base $23.74
Margin and raw-material legs dominate; the cycle leg is narrow because volume is assumed to recover. No single driver comes within $8/share of the price.
Red = >15% below price. Stable WACC capped at 8.75%. Even 13.5% forever at an 8.25% WACC (~$33) leaves the price outside the grid.
10-yr history — revenue ($M, bars) vs clean EBIT margin (line)
Clean EBIT = GAAP operating income + goodwill impairments and discrete one-offs (nora inventory step-up/deal costs 2018, SEC fine 2020, cyber 2022–23). Restructuring is kept as a cost — Interface booked it in 10 of the last 10 years (avg $11.4M/yr).
What normalization says. The 5-yr window (2021–25) is not all-peak — it includes the 2023 trough (8.4%) — but its average (9.6%) and the 10-yr average (9.5%) agree, and both sit ~2.7pt below FY26E. Company AOI (which also adds back restructuring and purchase amortization) averages 10.8% — management's own "adjusted" history doesn't support 12%+ as mid-cycle either. No mid-cycle margin target has been published; FY26 guidance implies AOI ~$202M including the refund. Our base 11.5% sits between history and today; it is a generous normalization, not a punitive one.
FCF and FCF − SBC ($M)
Year
OCF
Capex
FCF
SBC
FCF − SBC
Yield on mkt cap
2021
86.7
28.1
58.6
5.5
53.1
2.6%
2022
43.1
18.4
24.6
8.5
16.1
0.8%
2023
142.0
26.1
115.9
10.3
105.7
5.2%
2024
148.4
33.8
114.6
12.9
101.7
5.0%
2025
167.9
46.2
121.7
14.4
107.3
5.3%
TTM
177.9
53.9
124.0
17.1
106.9
5.3%
Capex stepping up ($60M FY26 guide vs ~$40M D&A) for European/Australian automation — reinvestment the model funds via sales-to-capital 2.0. 2022's FCF collapse ($25M) is the working-capital face of a raw-material spike: inventory soaked up cash when nylon costs ran.
Base-case FCFF ($M)
Year
Revenue
EBIT %
EBIT
NOPAT
Reinvest
FCFF
WACC
PV
2027
1,499
12.1%
182
134
15
120
9.74%
109
2028
1,552
12.0%
186
137
26
111
9.74%
92
2029
1,614
11.8%
191
141
31
110
9.74%
83
2030
1,670
11.7%
195
144
28
116
9.74%
80
2031
1,721
11.5%
198
146
25
121
9.74%
76
2032
1,772
11.5%
204
151
26
125
9.54%
72
2033
1,825
11.5%
210
155
27
129
9.34%
68
2034
1,880
11.5%
216
160
27
133
9.15%
64
2035
1,927
11.5%
222
164
24
140
8.95%
62
2036
1,975
11.5%
227
168
24
144
8.75%
58
Terminal
g 2.5%, stable ROIC 12% → reinvest 21% of NOPAT, tax 26%, stable WACC 8.75%
TV 2,182
885
PV explicit 764 + PV terminal 885 = operating assets 1,649. Terminal share 54% (under 70% flag). Base year FY26E $1,470M (53-week year, so 2027 growth of 2% ≈ 4% underlying). Tax 26% per guidance. Yr-1 after-tax ROIC 15.1% on $887M invested capital — high, which is why we allow 11.5% margins; terminal ROIC 12% assumes some competitive fade.
Cost of capital
Risk-free (10Y UST after Sept-2026 spike; USD-consistent for all cash flows)
5.20%
Mature ERP
4.40%
Country risk (EAAA ~37%, mostly developed; small Asia exposure)